Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Inavolisib in Premature Ovarian Insufficiency
NCT07904208Phase 1Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Oct 2026
- Primary completion
- Jul 2027
01
Overview
Phase 1, open-label, single-arm trial of inavolisib in primary ovarian insufficiency (POI), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of treatment-emergent adverse events at 3 months and Change in total antral follicle count at 3 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
inavolisib
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT07904208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904208.